A Aforeworn
Forewarned is forearmed.
Home › Niches › Pharmacy & Controlled Substances › Change
Critical

Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications

Detected July 16, 2026 · in Pharmacy & Controlled Substances

FDA withdraws approval of 34 NDAs from Endo Operations Limited and others, removing these drugs from the market. Pharmacies must stop dispensing affected products immediately.

Aforeworn detected this change in the Pharmacy & Controlled Substances space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Critical. All pharmacies dispensing any of the 34 withdrawn drugs should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately upon publication (July 6, 2026). Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.

What changed

These drugs are no longer FDA-approved and cannot be legally marketed or dispensed.

Who it affects

All pharmacies dispensing any of the 34 withdrawn drugs

What you must do

Identify and quarantine any stock of the affected drugs; cease dispensing; return or destroy inventory per FDA guidance.

Deadline

Immediately upon publication (July 6, 2026)

Source: https://www.federalregister.gov/documents/2026/07/06/2026-13616/endo-operations-limited-et-al-withdrawal-of-approval-of-34-new-drug-applications

Never miss a change like this again

Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.

Start your free trial

Related changes in Pharmacy & Controlled Substances